Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that the Notice of Annual General Meeting (‘AGM’).
AbC-19TM test to monitor vaccine responses to variants of concern AbC-19TM able to detect antibody response to different vaccines as well as natural infection
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
FOR THE YEAR ENDED 31 MARCH 2021
Peer-reviewed performance evaluation and self-test user experience of AbC 19TM
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that following completion of the of US performance studies.
Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment that Mologic Ltd have requested for Porton Down to evaluate
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, provides the following update on VISITECT® COVID-19 Antigen test regulatory approvals.
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, provides the following update on its UK Government manufacturing contract.
